Unlocking The Potential Applications of SRGAP2 (G23380)

Target Name: SRGAP2

NCBI ID: G23380

SRGAP2

Unlocking The Potential Applications of SRGAP2

SRGAP2 (KIAA0456) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Kallikrein-related gene 2 (KLK2) family, which is characterized by the presence of a specific domain called the N-terminal hypervariable region (HVR1).

The N-terminal HVR1 region of SRGAP2 is a unique structural feature that is composed of a series of amino acids that are highly conserved across different species. This region is involved in the formation of a distinct protein structure that is distinct from other proteins that are expressed in the body.

One of the unique features of SRGAP2 is its ability to interact with other proteins that are expressed in the body. This interaction is mediated by the N-terminal HVR1 region, which is known as the N-terminal domain. The N-terminal domain is a structural element that is highly conserved across different species and is involved in the formation of a distinct protein structure that is distinct from other proteins that are expressed in the body.

Another feature is that SRGAP2 is susceptible to oxidative stress damage. Oxidative stress damages the homeostasis of cellular homeostasis, leading to cellular metabolic disorders and, in severe cases, cell death. The expression level of SRGAP2 can change under the influence of oxidative stress. Therefore, by studying the expression of SRGAP2 under oxidative stress conditions, we can understand the impact of oxidative stress on cells and provide new targets for the treatment of oxidative stress-related diseases.

SRGAP2 is also known as KIAA0456 and has been shown to play a role in a variety of physiological processes in the body, including cell signaling, cell adhesion, and neurotransmission. It is a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In cancer treatment, SRGAP2 is considered a potential tumor target. Studies have shown that the expression level of SRGAP2 can be affected by various cancer types, such as lung cancer, breast cancer, kidney cancer, etc. In addition, SRGAP2 is also related to the invasion and metastasis of tumor cells. Therefore, by studying the role of SRGAP2 in tumor treatment, more effective treatment options can be provided for tumor patients.

SRGAP2 is also considered a potential target in the treatment of neurodegenerative diseases. For example, some studies have shown that SRGAP2 can regulate the amount of neurons lost in neurodegenerative diseases. Therefore, by studying the role of SRGAP2 in the treatment of neurodegenerative diseases, more effective treatment options can be provided for patients with neurodegenerative diseases.

In the treatment of immune diseases, SRGAP2 is also considered a potential target. Studies have shown that SRGAP2 can participate in the regulation of immune cell differentiation and function. Therefore, by studying the role of SRGAP2 in the treatment of immune diseases, more effective treatment options can be provided for patients with immune diseases.

SRGAP2 is a protein expressed in a variety of tissues and organs and has multiple biological functions. Its unique characteristics include the ability to interact with proteins and susceptibility to oxidative stress damage. SRGAP2 has potential applications in the treatment of cancer, neurodegenerative diseases and immune diseases. By studying the biological functions and pharmacological properties of SRGAP2, new ideas can be provided for the development of new treatments and drugs.

Protein Name: SLIT-ROBO Rho GTPase Activating Protein 2

Functions: Postsynaptic RAC1 GTPase activating protein (GAP) that plays a key role in neuronal morphogenesis and migration mainly during development of the cerebral cortex (PubMed:20810653, PubMed:27373832, PubMed:28333212). Regulates excitatory and inhibitory synapse maturation and density in cortical pyramidal neurons (PubMed:22559944, PubMed:27373832). SRGAP2/SRGAP2A limits excitatory and inhibitory synapse density through its RAC1-specific GTPase activating activity, while it promotes maturation of both excitatory and inhibitory synapses through its ability to bind to the postsynaptic scaffolding protein HOMER1 at excitatory synapses, and the postsynaptic protein GPHN at inhibitory synapses (By similarity). Mechanistically, acts by binding and deforming membranes, thereby regulating actin dynamics to regulate cell migration and differentiation (PubMed:27373832). Promotes cell repulsion and contact inhibition of locomotion: localizes to protrusions with curved edges and controls the duration of RAC1 activity in contact protrusions (By similarity). In non-neuronal cells, may also play a role in cell migration by regulating the formation of lamellipodia and filopodia (PubMed:20810653, PubMed:21148482)

The "SRGAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SRGAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets